Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 167Neoplasm Metastasis 18Breast Neoplasms, Male 15Neoplasms 13Brain Neoplasms 11Inflammatory Breast Neoplasms 5Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Ovarian Neoplasms 2Osteitis Deformans 2Lung Neoplasms 2HER2 Positive Metastatic Breast Cancer 2Esophageal Neoplasms 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Ductal, Breast 2Breast Diseases 2Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Patient Compliance 1Neoplastic Cells, Circulating 1Metastatic Breast Cancer With Intracranial Metastases 1Invasive Breast Cancer 1Insulin-Like Growth Factor I, Resistance To 1Her2 Positive Metastatic Breast Cancer 1HER2-positive Advanced Breast Cancer 1HER2-Positive Early Stage Breast Cancer 1HER2+ Metastatic Breast Cancer (MBC) 1HER2 Positive Breast Cancer 1

Interventions

Lapatinib 2ribociclib 1Trastuzumab 1Paclitaxel 1Letrozole 1Goserelin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Osteitis Deformans × Lapatinib × Breast × Clear all
NCT00444535 2021-10-25

Lapatinib and Bevacizumab for Metastatic Breast Cancer

Novartis

Phase 2 Completed
52 enrolled 13 charts
Breast

Breast Neoplasms, Osteitis Deformans

NCT00553358 2021-09-21

Neo ALTTO

Novartis

Phase 3 Completed
455 enrolled 34 charts
Breast

Breast Neoplasms, Osteitis Deformans

Data powered by HemOnc (CC BY 4.0) Colophon âš¡